Jasper Therapeutics, Inc.
JSPR
$2.92
-$0.04-1.35%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -25.81% | 12.66% | -30.50% | -27.80% | -6.23% |
| Total Depreciation and Amortization | -7.53% | 13.88% | -54.71% | 80.94% | 3.82% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 6.49% | -5.07% | 0.38% | 31.27% | 24.67% |
| Change in Net Operating Assets | 328.58% | -567.39% | -57.19% | 93.71% | 127.98% |
| Cash from Operations | 32.35% | -8.08% | -50.40% | -20.31% | 25.78% |
| Capital Expenditure | -- | -- | 64.96% | -74.52% | -528.00% |
| Sale of Property, Plant, and Equipment | 100.00% | -80.00% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -75.00% | 105.26% | 72.26% | -74.52% | -528.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | 3,733.33% | -95.03% | -99.62% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | 3,733.33% | -95.03% | -99.62% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 59.33% | -9.46% | -45.74% | -22.83% | -136.90% |